The purpose of this study is to determinate the effect of a pre-treatment with the combined serotonin (5-HT) and norepinephrine (NE) transport blocker duloxetine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The investigators hypothesize that duloxetine will attenuate the subjective and cardiovascular response to MDMA.
3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is widely used by young people for its euphoric effects. MDMA releases serotonin (5-HT), norepinephrine (NE), and dopamine through an interaction with the corresponding presynaptic monoamine uptake transporter. 5-HT transport inhibitors block MDMA-induced 5-HT release in vitro or in animals and also attenuate the subjective and cardiovascular response to MDMA in humans. NE transport inhibitors similarly prevent the MDMA-induced release of NE in cell assays and attenuate behavioral effects of MDMA in animals. Effects of the NE transporter inhibitor reboxetine on the response to MDMA in humans are currently investigated. Here we suggest evaluating effects of pretreatment with the combined 5-HT and NE transport blocker duloxetine on the pharmacodynamics and pharmacokinetics of MDMA. The study will use a randomized double-blind cross-over design with four experimental sessions. Duloxetine (120 mg) or placebo will be administered 16 h and 4 h before the administration of MDMA (125 mg) or placebo to 16 healthy volunteers. Subjective and cardiovascular responses and plasma samples for pharmacokinetics will be repeatedly assessed throughout the experiments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
16
125 mg, single dose
120 mg two doses 12h and 2h before MDMA
capsules identical to MDMA or duloxetine
Clinical Pharmacology & Toxicology, University Hospital Basel
Basel, Basel, Switzerland
Effect of duloxetine on the subjective response to MDMA
Time frame: 24h
Effect of duloxetine on cardiovascular effects of MDMA
Time frame: 6h
Effect of duloxetine on pharmacokinetics of MDMA
Time frame: 6h
Effect of MDMA on duloxetine pharmacokinetics
Time frame: 6h
Tolerability of MDMA and duloxetine
Time frame: 7 days
Effect of duloxetine on neuroendocrine responses to MDMA
Time frame: 6h
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.